Food and Drugs Administration

Gastrointenstinal Drugs Advisory Committee

June 25, 2003

Slides

Serostim®

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Serostim® [somatropin (rDNA orgin) for injection] Indicated for the Treatment of Short Bowel Syndrome in Patients - Proposed Indication, Pamela Joyce, Serono (HTM) (PPT)

Backup Slides Used in Q&A, Serono (HTM) (PPT)

Treatment of Short Bowel Syndrome, Dr. Hugo Gallo-Torres, MD, PhD, PNS, FDA (HTM) (PPT)

Serostim® Questions for AC, Dr. Robert Justice, MD, FDA (HTM) (PPT)